Focusing on outcomes in circulation: Cardiovascular quality and outcomes

Circulation: Cardiovascular Quality and Outcomes

Volumn 3, Issue 4, 2010, Pages 332-334

  Krumholz, Harlan M ^a,b  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b 1 Church St Suite 200 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN;

ADVERSE OUTCOME; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CIRCULATION; COST EFFECTIVENESS ANALYSIS; EDITORIAL; FOOD AND DRUG ADMINISTRATION; MOTOR NEURON DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; SMOKING; CONVALESCENCE; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; HEALTH CARE QUALITY; HUMAN; METABOLISM; MORTALITY; PATIENT SATISFACTION; QUALITY OF LIFE;

BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; HUMANS; MORTALITY; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; QUALITY OF HEALTH CARE; QUALITY OF LIFE; RECOVERY OF FUNCTION;

EID: 77957886848     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.110.958017     Document Type: Editorial

References (39)

1. Pearson TA, Denke MA, McBride PE, Battisti WP, Gazzara RA, Brady WE, Palmisano J. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: A substudy of the Ezetimibe Add-on to Statin for Effectiveness Trial. Mayo Clin Proc. 2006;81:1177-1185.
2. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-1456.
3. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons- Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
4. Maddox TM, Ross C, Tavel HM, Lyons EE, Tillquist M, Ho PM, Rumsfeld JS, Margolis KL, O'Connor PJ, Selby JV, Magid DJ. Blood pressure trajectories and associations with treatment intensification, medication adherence, and outcomes among newly diagnosed coronary artery disease patients. Circ Cardiovasc Qual Outcomes. 2010;3:347-357.
5. Dai J, Lampert R, Wilson PW, Goldberg J, Ziegler TR, Vaccarino V. Mediterranean dietary pattern is associated with improved cardiac autonomic function among middle-aged men: A twin study. Circ Cardiovasc Qual Outcomes. 2010;3:366-373.
6. Angell SY, Garg RK, Gwynn RC, Bash L, Thorpe LE, Frieden TR. Prevalence, awareness, treatment, and predictors of control of hypertension in New York City. Circ Cardiovasc Qual Outcomes. 2008;1: 46-53.
7. Rinfret S, Lussier M-T, Peirce A, Duhamel F, Cossette S, Lalonde L, Tremblay C, Guertin M-C, LeLorier J, Turgeon J, Hamet P; for the LOYAL Study Investigators. The impact of a multidisciplinary information technology-supported program on blood pressure control in primary care. Circ Cardiovasc Qual Outcomes. 2009;2:170-177.
8. Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E. Serum selenium concentrations and hypertension in the US population. Circ Cardiovasc Qual Outcomes. 2009;2:369-376.
9. Kressin NR, Orner MB, Manze M, Glickman ME, Berlowitz D. Understanding contributors to racial disparities in blood pressure control. Circ Cardiovasc Qual Outcomes. 2010;3:173-180.
10. Groom RC, Quinn RD, Lennon P, Donegan DJ, Braxton JH, Kramer RS, Weldner PW, Russo L, Blank SD, Christie AA, Taenzer AH, Forest RJ, Clark C, Welch J, Ross CS, O'Connor GT, Likosky DS; for the Northern New England Cardiovascular Disease Study Group. Detection and elimination of microemboli related to cardiopulmonary bypass. Circ Cardiovasc Qual Outcomes. 2009;2:191-198.
11. Steiner JF, Ho PM, Beaty BL, Dickinson LM, Hanratty R, Zeng C, Tavel HM, Havranek EP, Davidson AJ, Magid DJ, Estacio RO. Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes. 2009;2:451-457.
12. Lopez-Jimenez F, Batsis JA, Roger VL, Brekke L, Ting HH, Somers VK. Trends in 10-year predicted risk of cardiovascular disease in the United States, 1976 to 2004. Circ Cardiovasc Qual Outcomes. 2009;2:443-450.
13. Marma AK, Berry JD, Ning H, Persell SD, Lloyd-Jones DM. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: Findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcomes. 2010;3:8-14.
14. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R Sr, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1:92-97.
15. Nasir K, McClelland RL, Blumenthal RS, Goff DC Jr, Hoffmann U, Psaty BM, Greenland P, Kronmal RA, Budoff MJ. Coronary artery calcium in relation to initiation and continuation of cardiovascular preventive medications: The Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Qual Outcomes. 2010;3:228-235.
16. Kallio K, Jokinen E, Saarinen M, Hamalainen M, Volanen I, Kaitosaari T, Ronnemaa T, Viikari J, Raitakari OT, Simell O. Arterial intima-media thickness, endothelial function, and apolipoproteins in adolescents frequently exposed to tobacco smoke. Circ Cardiovasc Qual Outcomes.2010;3:196-203.
17. Spencer FA, Goldberg RJ, Lessard D, Reed G, Emery C, Gore JM, Pacifico L, Weitz JI. Factors associated with adverse outcomes in outpatients presenting with pulmonary embolism: The Worcester Venous Thromboembolism Study. Circ Cardiovasc Qual Outcomes. 2010;3: 390-394.
18. Fosbøl EL, Folke F, Jacobsen S, Rasmussen JN, Sørensen R, Schramm TK, Andersen SS, Rasmussen S, Poulsen HE, Køber L, Torp-Pedersen C, Gislason GH. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes. 2010;3:395-405.
19. Pottala JV, Garg S, Cohen BE, Whooley MA, Harris WS. Blood eicosapentaenoic and docosahexaenoic acids independently predict all-cause mortality in patients with stable coronary heart disease: The Heart and Soul Study. Circ Cardiovasc Qual Outcomes. 2010;3:406-412.
20. Amin AP, Marso SP, Rao SV, Messenger J, Chan PS, House J, Kennedy K, Robertus K, Cohen DJ, Mahoney E. Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. Circ Cardiovasc Qual Outcomes. 2010;3:358-365.
21. Sørensen HT, Riis AH, Lash TL, Pedersen L. Statins use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3:413-417.
22. Keenan PS, Normand SL, Lin Z, Drye EE, Bhat KR, Ross JS, Schuur JD, Stauffer BD, Bernheim SM, Epstein AJ, Wang Y, Herrin J, Chen J, Federer JJ, Mattera JA, Krumholz HM. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes. 2008;1:29-37.
23. Arnold SV, Morrow DA, Lei Y, Cohen DJ, Mahoney EM, Braunwald E, Chan PS. Economic impact of angina after an acute coronary syndrome: Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes. 2009;2:344-353.
24. Norris CM, Spertus JA, Jensen L, Johnson J, Hegadoren KM, Ghali WA. Sex and gender discrepancies in health-related quality of life outcomes among patients with established coronary artery disease. Circ Cardiovasc Qual Outcomes. 2008;1:123-130.
25. Venkitachalam L, Kip KE, Mulukutla SR, Selzer F, Laskey W, Slater J, Cohen HA, Wilensky RL, Williams DO, Marroquin OC, Sutton-Tyrrell K, Bunker CH, Kelsey SF. Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: A report from the National Heart, Lung, and Blood Institute-sponsored 1997-2006 Dynamic Registry. Circ Cardiovasc Qual Outcomes. 2009;2: 607-615.
26. Gulliksson M, Wedel H, Koster M, Svardsudd K. Hazard function and secular trends in the risk of recurrent acute myocardial infarction: 30 years of follow-up of more than 775,000 incidents. Circ Cardiovasc Qual Outcomes. 2009;2:178-185.
27. Lewsey JD, Jhund PS, Gillies M, Chalmers JW, Redpath A, Kelso L, Briggs A, Walters M, Langhorne P, Capewell S, McMurray JJ, MacIntyre K. Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. Circ Cardiovasc Qual Outcomes. 2009;2:475-483.
28. Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB, Anand IS, Hart R, Connolly SJ. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3:277-283.
29. Girard LP, Feasby TE, Eliasziw M, Quan H, Kennedy J, Barnett HJ, Ghali WA. Complication rates after left- versus right-sided carotid endarterectomy. Circ Cardiovasc Qual Outcomes. 2009;2:642-647.
30. Reed SD, Whellan DJ, Li Y, Friedman JY, Ellis SJ, Piña IP, Settles SJ, Davidson-Ray L, Johnson JL, Cooper LS, O'Connor CM, Schulman KA; HF-ACTION Investigators. Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: An exercise training study of patients with chronic heart failure. Circ Cardiovasc Qual Outcomes. 2010;3:374-381.
31. Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2:65-72.
32. Merchant RM, Becker LB, Abella BS, Asch DA, Groeneveld PW. Cost-effectiveness of therapeutic hypothermia after cardiac arrest. Circ Cardiovasc Qual Outcomes. 2009;2:421-428.
33. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotypeguided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2009;2:429-436.
34. Weintraub WS, Boden WE, Zhang Z, Kolm P, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008;1:12-20.
35. Diamond GA, Kaul S. Cost, effectiveness, and cost-effectiveness. Circ Cardiovasc Qual Outcomes. 2009;2:49-54.
36. Weintraub WS, Cohen DJ. The limits of cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2009;2:55-58.
37. Bradley SM, Levy WC, Veenstra DL. Cost-consequences of ultrafiltration for acute heart failure: A decision model analysis. Circ Cardiovasc Qual Outcomes. 2009;2:566-573.
38. Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, Eagle K, Mosse F, Jackson JD, Steg PG, Bhatt DL. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1:38-45.
39. Whellan DJ, Greiner MA, Schulman KA, Curtis LH. Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004. Circ Cardiovasc Qual Outcomes. 2010;3:33-40.